Want to see IT:DIA full AI Analyst Report?
Top Page
DiaSorin S.p.A.
(DIA)
Select Model
Select Model
Rating:73Outperform
Price Target:
€84.00
▲(25.86% Upside)
Action:Upgraded
Date:08/10/26
The score is driven primarily by improving financial performance (strong TTM revenue rebound, strong cash conversion, and reduced leverage). Technicals add support with a clear uptrend and positive momentum, while valuation tempers the score due to a relatively higher P/E and modest dividend yield.
Positive Factors
Recurring Consumables Revenue
DiaSorin's business model earns a large portion of revenue from repeat purchases of reagents and assay kits used on installed instruments. This creates high revenue visibility and stickiness: once instruments are placed, ongoing utilization drives predictable, utilization-linked consumable demand over multiple years.
Negative Factors
Below-Peak Profitability
Net margin and ROE remain below the company's earlier cycle peaks, indicating profitability has not fully recovered. Sustained lower margins constrain retained earnings and returns to shareholders, and may reflect structural price/mix pressure or higher operating costs that could persist absent operational improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Consumables Revenue
DiaSorin's business model earns a large portion of revenue from repeat purchases of reagents and assay kits used on installed instruments. This creates high revenue visibility and stickiness: once instruments are placed, ongoing utilization drives predictable, utilization-linked consumable demand over multiple years.
Read all positive factors
DiaSorin S.p.A. (DIA) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€4.07B
Dividend Yield1.71%
Average Volume (3M)221.33K
Price to Earnings (P/E)23.5
Beta (1Y)0.25
Revenue Growth-3.13%
EPS Growth-22.16%
CountryIT
Employees3,260
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)3.21
Shares Outstanding55,948,257
10 Day Avg. Volume225,158
30 Day Avg. Volume221,334
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)2.42
Price to Sales (P/S)3.21
P/FCF Ratio18.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€65.47Price Target Upside-1.90% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)3.98
Revenue Forecast (FY)€1.23B
DiaSorin S.p.A. Business Overview & Revenue Model
Company Description
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, includ...
How the Company Makes Money
DiaSorin primarily makes money by selling in-vitro diagnostic solutions that combine (1) diagnostic instruments and (2) recurring consumables used on those instruments. A significant portion of revenue is typically driven by repeat purchases of re...
DiaSorin S.p.A. Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
67
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.74B | 1.20B | 1.19B | 1.15B | 1.36B | 1.24B |
| Gross Profit | 1.13B | 699.89M | 781.00M | 741.19M | 900.61M | 824.77M |
| EBITDA | 473.42M | 432.81M | 399.04M | 333.40M | 479.71M | 504.56M |
| Net Income | 211.26M | 155.62M | 188.10M | 159.85M | 240.91M | 310.97M |
Balance Sheet | ||||||
| Total Assets | 2.90B | 2.87B | 3.30B | 3.21B | 3.41B | 3.23B |
| Cash, Cash Equivalents and Short-Term Investments | 120.88M | 211.65M | 378.92M | 403.39M | 413.22M | 403.02M |
| Total Debt | 959.49M | 791.16M | 1.01B | 1.19B | 1.35B | 1.40B |
| Total Liabilities | 1.48B | 1.30B | 1.51B | 1.67B | 1.89B | 1.86B |
| Stockholders Equity | 1.42B | 1.58B | 1.80B | 1.54B | 1.52B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 410.90M | 205.08M | 239.07M | 266.20M | 275.65M | 283.29M |
| Operating Cash Flow | 480.03M | 342.76M | 358.78M | 311.66M | 389.34M | 400.66M |
| Investing Cash Flow | -193.62M | -144.52M | -49.81M | -29.10M | -231.95M | -1.61B |
| Financing Cash Flow | -326.10M | -351.18M | -259.13M | -235.96M | -333.04M | 1.26B |
DiaSorin S.p.A. Technical Analysis
Positive
66.74
Price Trends
70.45
Positive
67.36
Positive
66.38
Positive
Market Momentum
1.40
Positive
62.38
Neutral
79.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:DIA, the sentiment is Positive. The current price of 66.74 is below the 20-day moving average (MA) of 74.27, below the 50-day MA of 70.45, and above the 200-day MA of 66.38, indicating a bullish trend. The MACD of 1.40 indicates Positive momentum. The RSI at 62.38 is Neutral, neither overbought nor oversold. The STOCH value of 79.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:DIA.
DiaSorin S.p.A. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | €1.22B | 14.40 | 16.55% | 1.60% | 4.42% | -16.04% | |
75 Outperform | €10.88B | 21.69 | 24.25% | 2.61% | 9.10% | 22.99% | |
73 Outperform | €4.07B | 23.51 | 11.29% | 1.95% | -3.13% | -22.16% | |
65 Neutral | €781.34M | 14.85 | 12.37% | ― | -4.12% | 10.95% | |
60 Neutral | €3.21B | 40.81 | 6.80% | 2.63% | -0.48% | -42.84% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
43 Neutral | €9.50M | -0.27 | 17.04% | ― | 74.59% | ― |
* General Sector Average
IT:DIA
DiaSorin S.p.A.
75.96
-7.65
-9.15%
IT:AMP
Amplifon S.p.A.
11.86
-3.50
-22.77%
IT:ELN
El.En. S.p.A.
15.20
3.41
28.91%
IT:FDA
Fidia Spa
0.01
-0.28
-96.53%
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
52.70
1.08
2.09%
IT:SFL
Safilo Group SpA
1.85
0.34
22.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.